All In Biotech

Drug Trial Radar · NCT06984822

Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant

Evaluation of Serum and Ocular Coherence Tomography Biomarkers in Patients With Diabetic Macular Edema Treated With Anti-VEGF or Dexamethasone Implant

Last checked: Nov 20, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Aug 1, 2025

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Vastra Gotaland RegionGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
May 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to investigate the association between serum biomarkers and clinical response to anti-VEGF or dexamethasone implant by assessing OCT-biomarkers in patients with diabetic macular edema, DME, and to compare these with a group of naive patients (those not previously treated for DME).

Conditions

  • Diabetic Macular Edema
  • Visual Impairment
  • Diabetes Mellitus
  • Hyperglycaemia (Diabetic)
  • Oxidative Stress
  • Vascular Endothelial Growth Factor
  • VEGF

Interventions

  • Anti-VEGF treatmentDrug

    Treatment with intravitreal anti-VEGF treatment

  • Dexamethasone implantDevice

    Treatment with Dexamethasone implant

  • Treatment with intravitreal anti-VEGF OR Dexamethasone implantOther

    Treatment with intravitreal anti-VEGF OR treatment with Dexamethasone implant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Serum levels of Vascular Endothelial Growth Factor (VEGF)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)
  2. Serum levels of interleukin 6 (IL-6)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)
  3. Serum levels of interleukin 8 (IL-8)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)
  4. Serum levels of monocyte chemoattractant protein 1 (MCP-1)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)
  5. Serum levels of angiopoietin 2 (Ang-2)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)
  6. Serum levels of placental growth factor (PlGF)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)
  7. Serum levels of tumor necrosis factor alpha (TNF-a)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)
  8. Serum levels of intercellular adhesion molecule 1 (ICAM-1)Time frame: At baseline (and for group 3. naive patients also after 4 weeks)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sahlgrenska University Hospital, Department of Ophthalmology

    Mölndal, Sweden · Recruiting

  • Ögonmottagning Mölndal/SU

    Mölndal, Sweden · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.